Tralokinumab Improves Clinically Relevant Outcome Measures: A Post Hoc Analysis of ECZTRA 3, A Randomized Clinical Trial in Patients with Moderate-To-Severe Atopic Dermatitis

Main Article Content

Stephan Weidinger
Andrew Pink
Juan Francisco
Azra Kurbasic
Christina Olsen
Andreas Vilsbøll
Marjolein de Bruin Weller

Keywords

Atopic Dermatitis, Tralokinumab, efficacy

Abstract

Abstract not available.

References

1. Weidinger S, Novak N. Lancet 2016; 387: 1109–1122.

2. Silverberg JI et al. Ann Allergy Asthma Immunol 2018; 121: 340–347.

3. Dalgard FJ et al. J Invest Dermatol 2015; 135: 984–991.

4. Bieber T. Allergy 2020; 75: 54–62.

5. Tsoi LC et al. J Invest Dermatol 2019; 139: 1480–1489.

6. Weidinger S et al. Oral presentation at the American Academy of Dermatology Virtual Meeting, 2020.

7. Thyssen JP et al. J Eur Acad Dermatol Venereol 2020; doi: 10.1111/jdv.16716.

8. Chalmers JR et al. Br J Dermatol 2018; 178: e332–e341.